VBL Therapeutics is a leading clinical stage biotechnology company dedicated to developing and commercializing next-generation, targeted medicines for challenging medical conditions. As a publicly traded company (NASDAQ: VBLT), they are committed to the discovery and advancement of innovative therapies for people living with immune-inflammatory diseases. At VBL Therapeutics, their expertise in human biology has led to the creation of their proprietary Monocyte Targeting Technology (MTT), which is specifically designed to address chronic inflammation.

With a focus on targeted therapies, they aim to provide effective solutions for individuals suffering from immune-inflammatory conditions. One of their most promising products is VB-601, a targeted antibody for immune-inflammatory applications. This groundbreaking immunology candidate has demonstrated disease-modifying activity in various preclinical models, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.

VB-601 is set to enter Phase 1 clinical trials in the first quarter of 2023. Choose VBL Therapeutics for their commitment to transforming the lives of patients through innovative targeted therapies and their dedication to improving immune-inflammatory conditions